<DOC>
	<DOCNO>NCT00688012</DOCNO>
	<brief_summary>A placebo-controlled , double-blind , randomize , single dose , dose escalate trial healthy men evaluate safety , tolerability , pharmacokinetics pharmacodynamics SPC3649 .</brief_summary>
	<brief_title>Safety Study SPC3649 Healthy Men</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy Volunteers BMI : 1928 kg/m2 No clinically significant disease/disorder Screening laboratory test without clinically significant abnormality , must agree use condom intercourse one week study drug infusion Following receipt verbal write information study , subject must provide sign informed consent study related activity carry . Heavy exercise within past 7 day Alcohol intake &gt; 21 unit weekly Regular smoker Received experimental drug within 30 day study entry Planned participation experimental study study period HIVAb , HBsAg and/or HCV Ab positive History specific allergy Current use drug narcotic .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>antisense</keyword>
	<keyword>microRna antagonist</keyword>
	<keyword>anti-miR-122</keyword>
	<keyword>Safety healthy volunteer</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>